Age-related Changes in Central Blood Pressures

What happens when you combine NSAID type pain medication and aging-induced arterial stiffening? Can cyclooxygenase inhibitors cause hemodynamic problems in older adults? Editor-in-chief Bill Stanley interviews lead author Jill Barnes (Mayo Clinic) and expert Judy Delp (University of Florida) about the new human study by Barnes and colleagues which looked at the central blood pressure response to the COX inhibitor indomethacin in both old and young healthy adults.

Jill Nicole Barnes, Darren P. Casey, Caesy N. Hines, Wayne T. Nicholson, and Michael J. Joyner Cyclooxygenase Inhibition Augments Central Blood Pressure and Aortic Wave Reflection in Aging Humans Am J Physiol Heart Circ Physiol, published online April 13, 2012, doi: 10.1152/ajpheart.00032.2012.

00:0000:00

Cytochrome P450 2C9 and Coronary Resistance Vessel Tone

Understanding the underlying mechanisms of increased coronary blood flow during exercise is the pursuit of many cardiovascular researchers worldwide. Here, Associate Editor Masafumi Kitakaze interviews lead author Dirk Duncker (Erasmus University Medical Center) and expert Masaru Sugimachi (National Cardiovascular Center, Osaka) about the new study by Zhou et al on the vasodilator and vasoconstrictor metabolites produced by cytochrome P-450 (CYP) 2C9 in pigs both at rest and during exercise. Listen in to learn how Duncker and colleagues used innovative in vivo and in vitro experimental conditions, achieving surprisingly different results related to the effects of sulfaphenazole in the presence of combined NOS/COX blockade.

Zhichao Zhou, Veemal Hemradj, Vincent J. de Beer, Fen Gao, Maaike Hoekstra, Daphne Merkus, and Dirk J. Duncker Cytochrome P-450 2C9 exerts a vasoconstrictor influence on coronary resistance vessels in swine at rest and during exercise Am J Physiol Heart Circ Physiol, published online February 3, 2012, doi:10.1152/ajpheart.00648.2011.

00:0000:00

Neuregulin1/ErbB4 Signaling and Cardiomyocyte Proliferation

How is cardiac neuregulin signaling involved after herceptin treatment of breast cancer patients? Our latest podcast explores the new Review article by Wadugu et al, which focuses on neuregulin signaling in the heart and dissects early observations that up to 30% of patients treated with herceptin for breast cancer displayed heart failure as a side-effect, likely by inhibiting neuregulin signaling. Cardiomyocyte proliferation is just one of many events triggered by neuregulin activation in heart cells, thereby opening a safe, paracrine possibility to stimulate myocyte proliferation in experimental and clinical heart failure studies. Listen as Associate Editor Leon de Windt talks with senior author Bernhard Kuhn (Children's Hospital Boston/Harvard Medical School) and leading expert Douglas Sawyer (Vanderbilt University) about stem cell treatments, clinical trials, and much more.

Brian Wadugu and Bernhard Kuhn. The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation Am J Physiol Heart Circ Physiol, published ahead of print March 16, 2012, doi: 10.1152/ajpheart.00063.2012.

00:0000:00